Certara (NASDAQ:CERT) Updates FY24 Earnings Guidance

Certara (NASDAQ:CERTGet Free Report) updated its FY24 earnings guidance on Tuesday. The company provided earnings per share guidance of $0.41-0.46 for the period, compared to the consensus earnings per share estimate of $0.44. The company issued revenue guidance of $385-400 million, compared to the consensus revenue estimate of $391.05 million. Certara also updated its FY 2024 guidance to 0.410-0.460 EPS.

Analysts Set New Price Targets

Several research firms recently commented on CERT. KeyCorp raised shares of Certara from a sector weight rating to an overweight rating and set a $23.00 target price on the stock in a report on Wednesday, April 10th. Barclays reduced their target price on shares of Certara from $18.00 to $16.00 and set an equal weight rating on the stock in a report on Friday, June 28th. Finally, JMP Securities began coverage on shares of Certara in a report on Thursday, April 4th. They set a market perform rating on the stock. Seven equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of Hold and a consensus price target of $19.81.

View Our Latest Stock Report on Certara

Certara Trading Down 2.0 %

Shares of CERT opened at $14.02 on Wednesday. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.26 and a quick ratio of 3.26. The firm has a fifty day simple moving average of $15.65 and a two-hundred day simple moving average of $16.72. Certara has a twelve month low of $11.81 and a twelve month high of $19.87.

Certara (NASDAQ:CERTGet Free Report) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.01). The firm had revenue of $96.65 million for the quarter, compared to analysts’ expectations of $94.48 million. Certara had a negative net margin of 17.02% and a positive return on equity of 4.08%. As a group, equities analysts predict that Certara will post 0.28 earnings per share for the current fiscal year.

Certara Company Profile

(Get Free Report)

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

See Also

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.